These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25190137)

  • 1. Pharmacotherapy for treatment of retinal vein occlusion.
    Sarao V; Bertoli F; Veritti D; Lanzetta P
    Expert Opin Pharmacother; 2014 Nov; 15(16):2373-84. PubMed ID: 25190137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best practices for treatment of retinal vein occlusion.
    Hahn P; Fekrat S
    Curr Opin Ophthalmol; 2012 May; 23(3):175-81. PubMed ID: 22450223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis.
    Qian T; Zhao M; Xu X
    J Clin Pharm Ther; 2017 Oct; 42(5):519-529. PubMed ID: 28639290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroids and macular edema from retinal vein occlusion.
    Glacet-Bernard A; Coscas G; Zourdani A; Soubrane G; Souied EH
    Eur J Ophthalmol; 2011; 21 Suppl 6():S37-44. PubMed ID: 23264327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials.
    Chatziralli I; Nicholson L; Sivaprasad S; Hykin P
    Expert Opin Biol Ther; 2015; 15(12):1685-97. PubMed ID: 26358547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RETINAL VEIN OCCLUSIONS, FROM BASICS TO THE LATEST TREATMENT.
    Ho M; Liu DT; Lam DS; Jonas JB
    Retina; 2016 Mar; 36(3):432-48. PubMed ID: 26716954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
    Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
    Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study.
    Adelman RA; Parnes AJ; Bopp S; Saad Othman I; Ducournau D
    Biomed Res Int; 2015; 2015():870987. PubMed ID: 25705695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
    Sohn HJ; Han DH; Lee DY; Nam DH
    Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for retinal vein occlusion.
    Bremond-Gignac D
    Expert Opin Investig Drugs; 2016 Jul; 25(7):841-50. PubMed ID: 27153189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials in Branch Retinal Vein Occlusion.
    Panakanti TK; Chhablani J
    Middle East Afr J Ophthalmol; 2016; 23(1):38-43. PubMed ID: 26957837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retinal vein occlusion: anti-VEGF treatments].
    Nghiem-Buffet S; Cohen SY
    J Fr Ophtalmol; 2009 Nov; 32(9):679-86. PubMed ID: 19879018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis.
    Lu Y; Su L; Xu X
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):702-8. PubMed ID: 23746130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pharmaceuticals for the management of retinal vein occlusion and linked disorders.
    Driban M; Kedia N; Arora S; Chhablani J
    Expert Rev Clin Pharmacol; 2023; 16(11):1125-1139. PubMed ID: 37933706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion.
    Ozkiris A; Evereklioglu C; Erkilic K; Dogan H
    Eye (Lond); 2006 Jan; 20(1):13-7. PubMed ID: 15723039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.
    Nghiem-Buffet S; Baillif S; Regnier S; Skelly A; Yu N; Sodi A
    Eye (Lond); 2017 Apr; 31(4):551-559. PubMed ID: 27911446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Be cautious of using anti-vascular endothelial growth factor therapy for treatment of macular edema secondary to retinal vein occlusion].
    Sun XD; Gong YY; Wang FH
    Zhonghua Yan Ke Za Zhi; 2010 Feb; 46(2):100-2. PubMed ID: 20388340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.